CN1805739A - 消炎镇痛贴剂 - Google Patents
消炎镇痛贴剂 Download PDFInfo
- Publication number
- CN1805739A CN1805739A CNA2004800164330A CN200480016433A CN1805739A CN 1805739 A CN1805739 A CN 1805739A CN A2004800164330 A CNA2004800164330 A CN A2004800164330A CN 200480016433 A CN200480016433 A CN 200480016433A CN 1805739 A CN1805739 A CN 1805739A
- Authority
- CN
- China
- Prior art keywords
- inflammatory analgesic
- compatibility
- weight
- adhesive patch
- menthol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 36
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 36
- 239000000853 adhesive Substances 0.000 title claims abstract description 29
- 230000001070 adhesive effect Effects 0.000 title claims abstract description 29
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims abstract description 53
- 230000000694 effects Effects 0.000 claims abstract description 38
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960005274 benzocaine Drugs 0.000 claims abstract description 26
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims abstract description 21
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims abstract description 18
- 229960001047 methyl salicylate Drugs 0.000 claims abstract description 14
- 239000004615 ingredient Substances 0.000 claims abstract description 13
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002504 capsaicin Drugs 0.000 claims abstract description 9
- 235000017663 capsaicin Nutrition 0.000 claims abstract description 9
- 239000010642 eucalyptus oil Substances 0.000 claims abstract description 9
- 229940044949 eucalyptus oil Drugs 0.000 claims abstract description 9
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 37
- 230000007794 irritation Effects 0.000 claims description 23
- 239000010238 camphora Substances 0.000 claims description 22
- 229940025250 camphora Drugs 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 18
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 claims description 12
- 230000000638 stimulation Effects 0.000 claims description 12
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000002085 irritant Substances 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 231100000021 irritant Toxicity 0.000 abstract description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 abstract 2
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 abstract 2
- 229940007061 capsicum extract Drugs 0.000 abstract 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 abstract 1
- 229960002389 glycol salicylate Drugs 0.000 abstract 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 abstract 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 abstract 1
- 235000019477 peppermint oil Nutrition 0.000 abstract 1
- -1 polypropylene Polymers 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 14
- 239000004744 fabric Substances 0.000 description 14
- 239000010408 film Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000013521 mastic Substances 0.000 description 9
- 239000002674 ointment Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 229920002125 Sokalan® Polymers 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000004584 polyacrylic acid Substances 0.000 description 5
- 229920000139 polyethylene terephthalate Polymers 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920003051 synthetic elastomer Polymers 0.000 description 4
- 239000005061 synthetic rubber Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 229910001051 Magnalium Inorganic materials 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 230000036413 temperature sense Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- WHSXTWFYRGOBGO-UHFFFAOYSA-N 3-methylsalicylic acid Chemical compound CC1=CC=CC(C(O)=O)=C1O WHSXTWFYRGOBGO-UHFFFAOYSA-N 0.000 description 2
- BBMFSGOFUHEVNP-UHFFFAOYSA-N 4-hydroxy-2-methylbenzoic acid Chemical compound CC1=CC(O)=CC=C1C(O)=O BBMFSGOFUHEVNP-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 229910000323 aluminium silicate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 229940043276 diisopropanolamine Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- HDPLHDGYGLENEI-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COC(C)COCC1CO1 HDPLHDGYGLENEI-UHFFFAOYSA-N 0.000 description 1
- FVCHRIQAIOHAIC-UHFFFAOYSA-N 2-[1-[1-[1-(oxiran-2-ylmethoxy)propan-2-yloxy]propan-2-yloxy]propan-2-yloxymethyl]oxirane Chemical compound C1OC1COC(C)COC(C)COC(C)COCC1CO1 FVCHRIQAIOHAIC-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
- BRPCDOLEVHTTRE-UHFFFAOYSA-N 6-oxo-6-propan-2-yloxyhexanoic acid Chemical compound CC(C)OC(=O)CCCCC(O)=O BRPCDOLEVHTTRE-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010072132 Fracture pain Diseases 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- IJMWOMHMDSDKGK-UHFFFAOYSA-N Isopropyl propionate Chemical compound CCC(=O)OC(C)C IJMWOMHMDSDKGK-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002344 fibroplastic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920006284 nylon film Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940069762 swertia japonica extract Drugs 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
提供一种消炎镇痛贴剂,其在发挥优异消炎镇痛效果的同时,减轻了贴敷时不舒服的刺激感。具体地说,提供一种消炎镇痛贴剂,其特征在于作为有效成分配伍了苯佐卡因和具有抗刺激效果(Counter-irritation)的成分,具有抗刺激效果的成分是选自l-薄荷醇、dl-薄荷醇、dl-樟脑、d-樟脑、水杨酸甲酯、水杨酸羟乙酯、薄荷油、桉树油、辣椒碱、辣椒提取物、壬酸香草酰胺中的一种或两种以上;含有0.5~20重量%的苯佐卡因。
Description
技术领域
本发明涉及一种贴剂,其作为有效成分含有苯佐卡因和具有抗刺激效果(counter-irritation)的成分,用于肌肉疼痛、关节疼痛、腰痛、肩头发硬、骨折疼痛等。更详细的说,涉及减轻贴敷时的不良感觉、表现优异效果的消炎镇痛贴剂。
背景技术
一直以来,将配伍有l-薄荷醇、dl-樟脑、水杨酸甲酯等有效成分的药剂含有粘着层涂敷在不织布、织布、聚氯乙烯薄膜等载体上,再用聚丙烯薄膜、聚乙烯对苯二酸酯薄膜、纸等的剥离膜覆盖在药剂含有粘着层表面的各种消炎镇痛贴剂在市场上有售。
另外,作为在腰痛、肩头发硬等慢性疾病中广泛使用的温感型贴剂,其在上述有效成分的基础上、配伍了辣椒提取物、壬酸香草酰胺等温感刺激成分,也多在市场上有售。
在这些贴剂中配伍的l-薄荷醇、dl-樟脑、水杨酸甲酯、辣椒提取物、壬酸香草酰胺等所谓的具有抗刺激效果的成分、作为所谓的对抗刺激药被配伍进去。
具有抗刺激效果的成分、所谓的对抗刺激药是指,通过用于皮肤局部、引发轻度炎症,结果消除皮肤下组织充血的药剂;以减轻深部组织炎症为目的,刺激皮肤、引发轻度炎症的药剂。
但是,这种对抗刺激药,根据适用症状,由l-薄荷醇、水杨酸甲酯等有效成分的刺激,有时在患部会感到疼痛、有时会出斑疹。并且配伍有温感刺激成分的贴剂由于年龄、性别、贴敷部位的不同,温感的程度有时会相当不同,引起发红、斑疹等不舒服的皮肤刺激症状,成为问题。另外,也有在剥离了贴剂后,刺激残留、在洗澡时感到非常疼痛的情况。
为了减轻这样的刺激、疼痛,尝试过配伍各种生药成分、缓和刺激,但是到目前为止还没有得到充分的效果,需要研究改良品。
发明内容
发明预解决的课题
本发明鉴于上述现状,以提供在发挥优异消炎镇痛效果的同时、减轻贴敷时不良刺激感的消炎镇痛贴剂为课题。
为了解决上述课题,本发明者们对皮肤刺激的缓和进行了深入研究结果发现,配伍了有效成分的苯佐卡因、同时配伍了有效量的具有抗刺激效果的成分的贴剂,减轻了不舒服的刺激感、且能够充分发挥作为消炎镇痛被期待的效果,进而完成了本发明。
解决课题的手段
因此,本发明为一种消炎镇痛贴剂,其特征在于,作为基本形态配伍了苯佐卡因和具有抗刺激效果(counter-irritation)成分的有效成分。
具体地说,本发明为一种消炎镇痛贴剂,作为其有效量、含有0.5~20重量%的苯佐卡因。
更具体地说,本发明为一种消炎镇痛贴剂,与苯佐卡因一起,配伍了l-薄荷醇、dl-薄荷醇、dl-樟脑、d-樟脑、水杨酸甲酯、水杨酸羟乙酯、薄荷油、桉树油、辣椒碱、辣椒提取物、壬酸香草酰胺中的一种或两种以上的具有抗刺激效果的成分。
即,本发明的消炎镇痛贴剂的特征在于,在配伍了有效量的苯佐卡因的同时、还配伍了效量可期待的具有抗刺激效果的成分。
因此,更具体地说,本发明的消炎镇痛贴剂中具有抗刺激效果的成分的配伍量,l-薄荷醇、dl-薄荷醇、dl-樟脑、d-樟脑、水杨酸甲酯、水杨酸羟乙酯、薄荷油或桉树油为0.01~30重量%,辣椒碱、辣椒提取物或壬酸香草酰胺为0.001~5重量%。
进一步,以具体形态为基础,本发明为一种消炎镇痛剂,其特征在于,作为贴剂剂型为含有10~80重量%水分的水性泥敷剂,具体地说,在含有10~80重量%水分的水性泥敷剂膏体中,配伍0.5~20重量%的苯佐卡因、进一步配伍一种或两种以上选自l-薄荷醇、dl-薄荷醇、dl-樟脑、d-樟脑、水杨酸甲酯、水杨酸羟乙酯、薄荷油、桉树油、辣椒碱、辣椒提取物、壬酸香草酰胺的具有抗刺激效果的成分。
另外,作为其它形态,本发明也是一种苯佐卡因的使用方法,即用于缓和作为消炎镇痛贴剂的有效成分被含有的具有抗刺激效果的成分对皮肤的刺激感,联合使用苯佐卡因的方法。
发明的效果
通过本发明提供了一种消炎镇痛贴剂,其在发挥优异消炎镇痛效果的同时,减轻了贴敷时的不舒服的刺激感。特别是,本发明的贴剂是作为有效成分同时配伍有苯佐卡因和具有抗刺激效果的成分的贴剂,与以往的配伍有具有抗刺激效果的成分的制剂相比,有缓和皮肤刺激的效果,并且充分发挥被期待的消炎镇痛效果。
具体实施方式
以下详细说明本发明。
本发明所提供的消炎镇痛贴剂,其特征在于,作为有效成分、联合配伍了苯佐卡因和具有抗刺激效果的成分,在缓和了贴敷时的皮肤刺激感的同时,发挥优异的消炎镇痛效果。
为了上述目的所使用的苯佐卡因的配伍量在制剂中优选为0.5~20重量%,更优选为5~15重量%。苯佐卡因的配伍量小于0.5重量%时、则无法得到充分的消炎镇痛效果,超过20重量%时、变得无法得到制剂的稳定性,因此不优选。
另外一方面,在本发明的贴剂中,作为与苯佐卡因同时配伍的具有抗刺激效果的成分,可以举出l-薄荷醇、dl-薄荷醇、dl-樟脑、d-樟脑、水杨酸甲酯、水杨酸羟乙酯、薄荷油、桉树油、辣椒碱、辣椒提取物、壬酸香草酰胺,可以使用这些成分的一种或两种以上。
这些具有抗刺激效果的成分的配伍量,可以是在消炎镇痛贴剂中通常被配伍的量。具体地说,l-薄荷醇、dl-薄荷醇、dl-樟脑、d-樟脑、水杨酸甲酯、水杨酸羟乙酯、薄荷油、桉树油在制剂中优选为0.01~30重量%,更优选为0.1~15重量%。另外,辣椒碱、辣椒提取物、壬酸香草酰胺在制剂中优选为0.001~5重量%,更优选为0.005~3重量%。
不足上述配伍量的话、作为贴剂不能发挥这些成分的抗刺激效果;超过上述配伍量的话、则变成皮肤刺激强的贴剂,不优选。
在本发明提供的消炎镇痛贴剂中,在上述成分的基础上,可以配伍外用制剂中通常配伍的各种成分。作为这样的成分具体的可以举出具有促进血液循环作用的维生素E等的维生素E类、烟酰胺、烟酸苄酯等;具有镇痛消炎作用的乌拉尔甘草次酸、甘草酸、甘草酸二钾等;具有抗过敏作用的苯海拉明、扑尔敏等;还有山金车酊、黄柏皮提取物、甘菊提取物、栀子果实提取物、花椒果实提取物、紫草根茎提取物、七叶树种子提取物、日本当药提取物等植物提取物;作为防腐剂的尼泊金甲酯、对羟基苯甲酸乙酯、尼泊金丙酯、尼泊金丁酯等的对羟苯甲酸酯类,苯氧乙醇、苯甲酸、水杨酸、氯化苄乙氧铵、西氯吡铵、盐酸洗必太等;作为抗氧化剂的羟基茴香二丁酯、二丁基羟基甲苯、维生素C、维生素C钠等。
作为本发明提供的消炎镇痛贴剂的剂型可以举出泥敷剂、膏剂、胶带剂等。作为此基剂所使用的成分可以使用作为以往贴剂基剂中通常使用的物质。
具体地说,例如在水溶性泥敷剂中配伍明胶、支链淀粉、聚烯吡酮、聚乙烯醇、甲基纤维素、乙基纤维素、羧甲基纤维素、羟乙基纤维素、羟丙基纤维素、聚丙烯酸、聚丙烯酸钠、丙烯酸共聚物、马来酸酐共聚物、淀粉-丙烯酸钠接枝共聚物、聚羧乙烯、海藻酸钠、黄胞胶、琼脂、角叉藻聚糖等中的一种或两种以上的水溶性高分子物质。其配伍量随着基剂强度和制冷量、或制造时的操作性等有所不同,但通常是相对于膏体的总重量为3~40重量%。
在将由上述水溶性高分子物质形成的水性泥敷剂的基剂成分进行架桥时,使用钾明矾、铝明矾、氯化镁、氯化钙、氯化铝、氢氧化铝、氢氧化钙、氢氧化铁、磷酸钙、柠檬酸钙、甘氨酸铝、偏硅酸铝镁、镁的铝矽酸盐、硅酸铝、硅酸镁、合成铝碳酸镁等的多价金属,或者聚乙二烯醇二缩水甘油醚、乙二烯醇二缩水甘油醚、丙二醇二缩水甘油醚、三丙二醇二缩水甘油醚等的架桥剂,这些架桥剂的配伍量相对于膏体总重量优选为0.001~5重量%,更优选为0.005~3重量%。这些架桥剂可以一种单独使用、也可以适当组合两种以上进行使用。
使用上述架桥剂时优选配伍架桥调整剂。这种架桥调整剂可以使用柠檬酸、苹果酸、酒石酸、羟乙酸、富马酸、琥珀酸、依地酸等的有机酸或其盐类等。这些架桥调整剂可以一种单独使用、也可以适当组合两种以上进行使用。
并且,在基剂中可以配伍白陶土、膨润土、氧化钛等的无机盐和通常作为吸收辅助剂使用的蓖麻油、克罗米通、十四(烷)酸异丙酯、己二酸异丙酯、癸二酸二异丙酯、二异丙醇胺、N,N-二乙基间甲苯酰胺等,其配伍量相对于膏体总重量为0.01~20重量%,优选为0.1~10重量%。另外,还可以配伍乙二醇、二乙二醇、聚乙二醇、丙二醇、聚丙二醇、1,3-丁二醇、丙三醇、山梨醇等的多元醇。在配伍多元醇时,相对于膏体总重量优选为3~60重量%,更优选为10~50重量%。
在本发明提供的消炎镇痛贴剂中,其一形态的水性泥敷剂是含有水分的物质,此水分含量相对于膏体总重量优选为10~80重量%,更优选为30~75重量%。
另外,上述水性泥敷剂的膏体pH可调至3.0~9.0,优选调至3.5~8,更优选调至4~7.5。pH不足3.0时酸性过强、产生皮肤刺激;超过9.0时会发生对皮肤的腐蚀损伤等不好的作用,因此不优选。
作为上述水性泥敷剂的载体使用不织布、织布或它们与聚乙烯、聚丙烯、聚氯乙烯、聚偏二氯乙烯、聚氨基甲酸酯、聚对苯二甲酸乙酯的薄片制品等。其中特别优选不织布,作为不织布优选为由尼龙、乙烯叉、聚氯乙烯、聚酯、丙烯酸、聚乙烯、聚丙烯、聚氨基甲酸乙酯等的化学纤维、棉、羊毛、麻、绢等天然纤维中选择的至少一种纤维形成的不织布。
另外,在本发明提供的消炎镇痛贴剂的其它形态的膏剂,可以使用苯乙烯-异戊二烯-苯乙烯嵌段共聚物等的合成橡胶系粘合剂、天然橡胶粘合剂、加氢石油树脂、松香、加氢松香、聚乙烯醇、聚乙烯吡咯酮等粘合剂,此粘合剂的配伍量相对于膏体总重量可以是15~80重量%。
在上述膏剂中可以配伍聚丁烯、聚异丁烯等液体橡胶,液体石蜡,植物油,羊毛脂等的软化剂,此软化剂的配伍量相对于膏体总重量可以是10~40重量%。另外,根据需要,上述膏剂中还可以配伍脂肪酸酯类、高级醇等的经皮吸收促进剂,上述的在外用制剂中通常配伍的成分。
作为上述膏剂的载体可以使用纤维素衍生物薄膜、聚对苯二甲酸乙酯薄膜、尼龙薄膜、聚氯乙烯薄膜、聚乙烯薄膜、聚氨基甲酸酯薄膜、聚偏二氯乙烯薄膜等树脂薄膜、铝等的金属片材、不织布、织布等,树脂薄膜、金属片材可单独使用、也可与不织布层压后使用。
本发明提供的消炎镇痛贴剂的制造,例如水性泥敷剂时,可以通过充分混合苯佐卡因、具有抗刺激效果的成分、及所需的各种成分,调制成为如糊剂状后,以所需厚度将其涂敷、层压在纸、织布、不织布、塑料薄摩等的载体(基体材料)上,在用透明的保护膜如聚乙烯薄膜覆盖、裁剪成所需大小进行制造。作为药物含有膏体层、在基体材料片材上被层压的层的重量没有限定、作为涂敷量为200~2000g/m2、优选为400~1500g/m2即可。
另外,膏剂可以如下制造,例如将苯乙烯-异戊二烯-苯乙烯嵌段共聚物等的合成橡胶系粘合剂、软化基、增粘剂、抗氧化剂和填充剂等熔融混合,向其中加入苯佐卡因、具有抗刺激效果的成分、还有需要的各种成分,均一混合后,在载体膜上展开、截断成适宜的大小和形状。
实施例
以下,通过实施例和比较例具体说明本发明的消炎镇痛贴剂,但本发明并不受其限定。
实施例1~3:水性泥敷剂
如下述表1所示组成的水性泥敷剂按照平常方法调制,将其以均一厚度涂敷在不织布上、进一步用聚对苯二甲酸乙酯覆盖在其表面、得到实施例1~3的水性泥敷剂。
表1
成分 | 配伍(重量%) | ||
实施例1 | 实施例2 | 实施例3 | |
水杨酸甲酯 | 5.0 | - | 1.0 |
l-薄荷脑 | - | 1.0 | - |
dl-樟脑 | - | 1.0 | 1.0 |
辣椒提取物 | - | - | 0.3 |
苯佐卡因 | 5.0 | 5.0 | 5.0 |
蓖麻油 | 0.5 | 1.0 | 0.5 |
氢氧化铝 | 0.01 | 0.01 | 0.01 |
偏硅酸铝镁 | 0.03 | 0.03 | 0.03 |
聚丙烯酸部分中和物 | 5.0 | 5.0 | 5.0 |
聚丙烯酸 | 4.0 | 4.0 | 4.0 |
羧甲纤维素钠 | 3.0 | 3.0 | 3.0 |
丙三醇 | 16.0 | 16.0 | 16.0 |
酒石酸 | 0.5 | 0.5 | 0.5 |
N,N-二乙基间甲苯酰胺 | 6.0 | 6.0 | 6.0 |
依地酸钠 | 0.04 | 0.04 | 0.04 |
甲基对羟苯甲酸 | 0.15 | - | - |
丁羟基茴香醚 | - | 0.2 | - |
丁基羟甲苯 | - | 0.2 | - |
精制水 | 54.77 | 57.02 | 57.62 |
比较例1~3
如下述表2所示组成(不含苯佐卡因)的水性泥敷剂按照平常方法调制,将其以均一厚度涂敷在不织布上、进一步用聚对苯二甲酸乙酯覆盖在其表面、得到比较例1~3的水性泥敷剂。
表2
成分 | 配伍(重量%) | ||
比较例1 | 比较例2 | 比较例3 | |
水杨酸甲酯 | 5.0 | - | 1.0 |
l-薄荷脑 | - | 1.0 | - |
dl-樟脑 | - | 1.0 | 1.0 |
辣椒提取物 | - | - | 0.3 |
蓖麻油 | 0.5 | 1.0 | 0.5 |
氢氧化铝 | 0.01 | 0.01 | 0.01 |
偏硅酸铝镁 | 0.03 | 0.04 | 0.04 |
聚丙烯酸部分中和物 | 5.0 | 5.0 | 5.0 |
聚丙烯酸 | 4.0 | 4.0 | 4.0 |
羧甲纤维素钠 | 3.0 | 3.0 | 3.0 |
丙三醇 | 16.0 | 16.0 | 16.0 |
酒石酸 | 0.5 | 0.5 | 0.5 |
N,N-二甲基间甲苯酰胺 | 6.0 | - | - |
依地酸钠 | 0.04 | 0.04 | 0.04 |
甲基对羟苯甲酸 | 0.15 | - | - |
丁羟基茴香醚 | - | 0.2 | - |
丁基羟甲苯 | - | 0.2 | - |
精制水 | 59.77 | 68.01 | 68.61 |
实施例4:膏剂
按照下述处方,将苯乙烯-异戊二烯-苯乙烯嵌段共聚物、脂环饱和烃树脂、合成橡胶和二丁基羟甲苯熔融混合,再加入壬酸香草酰胺、水杨酸甲酯、dl-樟脑、苯佐卡因均一混合后,在载体膜上展开,得到膏剂。
处方:
壬酸香草酰胺 0.01重量%
水杨酸甲酯 5.0重量%
dl-樟脑 2.0重量%
苯佐卡因 5.0重量%
苯乙烯-异戊二烯-苯乙烯嵌段共聚物 22.0重量%
脂环饱和烃树脂 46.99重量%
合成橡胶 18.0重量%
二丁基羟甲苯 1.0重量%
试验例1:
将实施例1~3、比较例1~3的水性泥敷剂和实施例4的膏剂贴敷在20名被验者的上臂内侧,通过敏感试验分别对贴敷后10、20、30、60和90分钟后的刺激的强度进行评价。
刺激的评价标准分为以下的5级、为10名被验者的平均值。
4:强烈的疼痛
3:除了刺激外、感觉到疼痛
2:感觉到适度的刺激
1:感觉到很弱的刺激
0:没有感觉到刺激
其结果示于表3。
表3
10分钟后 | 20分钟后 | 30分钟后 | 60分钟后 | 90分钟后 | |
实施例1 | 1.2 | 1.9 | 2.2 | 2.2 | 2.2 |
实施例2 | 1.1 | 1.8 | 2.1 | 2.2 | 2.1 |
实施例3 | 1.1 | 1.9 | 2.2 | 2.1 | 2.2 |
实施例4 | 0.9 | 1.7 | 2.3 | 2.2 | 2.2 |
比较例1 | 1.1 | 2.5 | 3.1 | 3.2 | 3.2 |
比较例2 | 1.2 | 2.4 | 2.6 | 2.6 | 2.4 |
比较例3 | 1.3 | 1.8 | 2.6 | 2.7 | 2.7 |
由上述表3所示结果可知,本发明的贴剂(实施例1~4)在贴敷后20分钟左右表现出适度的刺激,与比较例相比,在30~90分钟的贴敷时间中对于刺激感觉到的疼痛少、持续了适度的刺激。
试验例2:
将实施例1和比较例1的贴剂使用于公司内10名具有关节疼痛症状的志愿者(在医生的监督下,得到允许后实施),评价其效果。
评价标准如下所示。
++:疼痛明显减轻
+:疼痛轻度减轻
±:没有变化
-:疼痛增加
其结果示于表4。
表4
评价标准 | 实施例1的贴剂 | 比较例1的贴剂 |
++ | 5 | 3 |
+ | 2 | 2 |
± | 3 | 5 |
- | 0 | 0 |
试验例3:
将实施例3和比较例3的贴剂使用于公司内10名具有腰疼症状的志愿者(在医生的监督下,得到允许后实施),评价其效果。
评价标准如下所示。
++:疼痛明显减轻
+:疼痛轻度减轻
±:没有变化
-:疼痛增加
其结果示于表5。
表5
评价标准 | 实施例3的贴剂 | 比较例3的贴剂 |
++ | 4 | 4 |
+ | 4 | 2 |
± | 2 | 4 |
- | 0 | 0 |
由上述表4和表5所示结果可知,本发明的贴剂与比较例的贴剂相比,对于关节疼痛、腰痛症状的有效率很高。
工业实用性
如上所述,本发明的贴剂作为有效成分配伍了苯佐卡因和具有抗刺激效果(Counter-irritation)的成分,与以往配伍了具有抗刺激效果的成分的制剂相比,具有缓和皮肤刺激效果,而且充分发挥了所期待的消炎镇痛效果。因此,其在医疗上的效果是非常大的。
Claims (7)
1.一种消炎镇痛贴剂,其特征在于作为有效成分配伍了苯佐卡因和具有抗刺激效果(Counter-irritation)的成分。
2.如权利要求1所述的消炎镇痛贴剂,其含有0.5~20重量%的苯佐卡因。
3.如权利要求1或2所述的消炎镇痛贴剂,具有抗刺激效果的成分为选自l-薄荷醇、dl-薄荷醇、dl-樟脑、d-樟脑、水杨酸甲酯、水杨酸羟乙酯、薄荷油、桉树油、辣椒碱、辣椒提取物、壬酸香草酰胺中的一种或两种以上。
4.如权利要求3所述的消炎镇痛贴剂,具有抗刺激效果的成分,l-薄荷醇、dl-薄荷醇、dl-樟脑、d-樟脑、水杨酸甲酯、水杨酸羟乙酯、薄荷油、桉树油的配伍量为0.01~30重量%,辣椒碱、辣椒提取物、壬酸香草酰胺的配伍量为0.001~5重量%。
5.如权利要求1~4任一项所述的消炎镇痛贴剂,剂型为含有10~80重量%水分的水性泥敷剂。
6.一种消炎镇痛贴剂,其特征在于在含有10~80重量%水分的水性泥敷剂中配伍有0.5~20重量%的苯佐卡因、还配伍有l-薄荷醇、dl-薄荷醇、dl-樟脑、d-樟脑、水杨酸甲酯、水杨酸羟乙酯、薄荷油、桉树油、辣椒碱、辣椒提取物、壬酸香草酰胺的具有抗刺激效果(Counter-irritation)的成分的一种或两种以上。
7.一种苯佐卡因的使用方法,其用于缓和作为消炎镇痛贴剂有效成分所含的具有抗刺激效果(Counter-irritation)的成分的刺激。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP166774/2003 | 2003-06-11 | ||
JP2003166774A JP4596751B2 (ja) | 2003-06-11 | 2003-06-11 | 消炎鎮痛貼付剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1805739A true CN1805739A (zh) | 2006-07-19 |
Family
ID=33549267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004800164330A Pending CN1805739A (zh) | 2003-06-11 | 2004-06-10 | 消炎镇痛贴剂 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070207088A1 (zh) |
EP (1) | EP1632226A4 (zh) |
JP (1) | JP4596751B2 (zh) |
KR (1) | KR100946605B1 (zh) |
CN (1) | CN1805739A (zh) |
CA (1) | CA2528649C (zh) |
TW (1) | TWI348383B (zh) |
WO (1) | WO2004110428A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101961418A (zh) * | 2010-08-17 | 2011-02-02 | 浙江省医学科学院 | 一种双控释高剂量低刺激性的辣椒碱复方透皮贴剂 |
CN106073982A (zh) * | 2016-06-16 | 2016-11-09 | 广州仁益医疗器械有限公司 | 阴囊医用降温贴 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006206471A (ja) * | 2005-01-26 | 2006-08-10 | Nitto Denko Corp | テープ製剤 |
DE102006060439A1 (de) | 2006-12-19 | 2008-06-26 | Henkel Kgaa | Verbesserung der Hautverträglichkeit von hyperämisierenden Wirkstoffen |
KR20100014511A (ko) * | 2007-05-17 | 2010-02-10 | 니프로 패치 가부시키가이샤 | 파프제 및 파프제 제조 방법 |
WO2009066146A2 (en) * | 2007-11-19 | 2009-05-28 | Cadila Pharmaceuticals Ltd. | Stable solutions of sparingly soluble actives |
KR101496499B1 (ko) * | 2008-01-31 | 2015-02-26 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 |
EP2098254A1 (de) | 2008-03-06 | 2009-09-09 | Bayer MaterialScience AG | Medizinische Klebstoffe für die Chirurgie mit bioaktiven Verbindungen |
JP5698120B2 (ja) * | 2008-04-15 | 2015-04-08 | フイルメニツヒ ソシエテ アノニムFirmenich Sa | 温感組成物 |
KR100976548B1 (ko) | 2008-09-12 | 2010-08-17 | 김희구 | 약재 성분의 방출이 조절되는 생약패드 및 이의 제조방법 |
EP2478897B1 (en) * | 2009-09-14 | 2018-03-07 | Hi Gu Kim | Pad for herbal medicine in which release of medicinal ingredient can be controlled, and manufacturing method thereof |
US10980752B2 (en) | 2009-09-14 | 2021-04-20 | Bm Biotechnology Co., Ltd. | Device for herbal medicine in which release of medicinal ingredient can be controlled, and manufacturing method thereof |
US8900646B2 (en) * | 2012-01-05 | 2014-12-02 | Danny Justman | Composition and method for minimizing bulling behavior of cattle |
US20160128950A1 (en) * | 2013-06-28 | 2016-05-12 | Sumair Mitroo | Tape having transdermal analgesic properties |
MA41266A (fr) * | 2014-12-22 | 2017-10-31 | Hisamitsu Pharmaceutical Co | Cataplasme |
WO2018198029A1 (en) * | 2017-04-25 | 2018-11-01 | Azista Industries Pvt Ltd | Matrix adhesive patch and process for the preparation thereof |
KR101882679B1 (ko) * | 2017-08-11 | 2018-07-27 | 이태완 | 저자극성 진통소염용 경피제제 및 이의 제조방법 |
WO2019146613A1 (ja) * | 2018-01-24 | 2019-08-01 | 久光製薬株式会社 | 貼付剤 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855294A (en) * | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
US4997853A (en) * | 1988-12-02 | 1991-03-05 | Galenpharma, Inc. | Method and compositions utilizing capsaicin as an external analgesic |
JP3214105B2 (ja) * | 1992-11-02 | 2001-10-02 | 大正製薬株式会社 | 架橋型ハップ基剤 |
JP3572765B2 (ja) * | 1994-12-19 | 2004-10-06 | 大正製薬株式会社 | パップ剤用膏体 |
US5859066A (en) * | 1996-04-08 | 1999-01-12 | Rutgers, The State University Of New Jersey | Method for the treatment of itching |
JP4677063B2 (ja) * | 1997-07-18 | 2011-04-27 | 帝國製薬株式会社 | オランダカラシエキス配合外用製剤 |
US5885597A (en) * | 1997-10-01 | 1999-03-23 | Medical Research Industries,Inc. | Topical composition for the relief of pain |
US6471984B1 (en) * | 1998-01-14 | 2002-10-29 | Hisamitsu Pharmaceutical Co., Inc. | Cataplasm and tape-aid containing a plasticizer |
US6120792A (en) * | 1998-04-29 | 2000-09-19 | Juni; Jack E. | Medicated skin patch and method for its use |
DE19833177A1 (de) * | 1998-07-23 | 2000-01-27 | Labtec Gmbh | Pflasterabdeckung nach Reizung |
US6284797B1 (en) * | 1999-04-12 | 2001-09-04 | Donald A. Rhodes | Topical treatment of pain and to promote healing |
JP4327958B2 (ja) * | 1999-10-20 | 2009-09-09 | 東光薬品工業株式会社 | 冷却貼付剤 |
EP1170020A4 (en) * | 1999-12-27 | 2009-05-06 | Teikoku Seiyaku Kk | EXTERNAL USE PADS |
JP2002119529A (ja) * | 2000-10-19 | 2002-04-23 | Toko Yakuhin Kogyo Kk | 冷却貼付剤用基材 |
US6902739B2 (en) * | 2001-07-23 | 2005-06-07 | Nutracea | Methods for treating joint inflammation, pain, and loss of mobility |
JP2003095985A (ja) * | 2001-09-26 | 2003-04-03 | Lion Corp | 血行促進組成物 |
US20030118655A1 (en) * | 2001-12-21 | 2003-06-26 | Nikhil Kundel | Film forming liquid composition |
JP2003250829A (ja) * | 2001-12-27 | 2003-09-09 | Lion Corp | 外用剤組成物 |
JP2003335663A (ja) * | 2002-05-20 | 2003-11-25 | Medorekkusu:Kk | 消炎鎮痛外用剤 |
JP2004123632A (ja) * | 2002-10-03 | 2004-04-22 | Medorekkusu:Kk | 消炎鎮痛外用剤 |
US20040191302A1 (en) * | 2003-03-28 | 2004-09-30 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US6865912B2 (en) * | 2002-12-27 | 2005-03-15 | Lg Electronics Inc. | Washing machine |
-
2003
- 2003-06-11 JP JP2003166774A patent/JP4596751B2/ja not_active Expired - Fee Related
-
2004
- 2004-06-10 WO PCT/JP2004/008097 patent/WO2004110428A1/ja active Application Filing
- 2004-06-10 TW TW093116629A patent/TWI348383B/zh not_active IP Right Cessation
- 2004-06-10 EP EP04745727A patent/EP1632226A4/en not_active Withdrawn
- 2004-06-10 US US10/560,471 patent/US20070207088A1/en not_active Abandoned
- 2004-06-10 KR KR1020057020411A patent/KR100946605B1/ko not_active IP Right Cessation
- 2004-06-10 CN CNA2004800164330A patent/CN1805739A/zh active Pending
- 2004-06-10 CA CA2528649A patent/CA2528649C/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101961418A (zh) * | 2010-08-17 | 2011-02-02 | 浙江省医学科学院 | 一种双控释高剂量低刺激性的辣椒碱复方透皮贴剂 |
CN101961418B (zh) * | 2010-08-17 | 2012-08-08 | 浙江省医学科学院 | 一种双控释高剂量低刺激性的辣椒碱复方透皮贴剂 |
CN106073982A (zh) * | 2016-06-16 | 2016-11-09 | 广州仁益医疗器械有限公司 | 阴囊医用降温贴 |
Also Published As
Publication number | Publication date |
---|---|
JP4596751B2 (ja) | 2010-12-15 |
JP2005002040A (ja) | 2005-01-06 |
EP1632226A4 (en) | 2006-07-12 |
WO2004110428A1 (ja) | 2004-12-23 |
KR100946605B1 (ko) | 2010-03-09 |
AU2004246924A1 (en) | 2004-12-23 |
US20070207088A1 (en) | 2007-09-06 |
EP1632226A1 (en) | 2006-03-08 |
KR20060017760A (ko) | 2006-02-27 |
CA2528649A1 (en) | 2004-12-23 |
TW200502009A (en) | 2005-01-16 |
TWI348383B (en) | 2011-09-11 |
CA2528649C (en) | 2013-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1805739A (zh) | 消炎镇痛贴剂 | |
JP5600141B2 (ja) | 冷却局所用貼付製剤 | |
CN102858379B (zh) | 粘合剂组合物 | |
CN102413821A (zh) | 经皮吸收型制剂 | |
CN1717226A (zh) | 温感敷剂 | |
CN107050048A (zh) | 一种冷敷贴及其制备方法 | |
CN106822988A (zh) | 海藻纤维功能性敷料及其应用、海藻纤维功能性敷料贴 | |
CN1703250A (zh) | 贴剂 | |
CN1048979A (zh) | 在人体组织上原位成膜的制剂和方法 | |
CN1303986C (zh) | 贴剂 | |
KR20060127779A (ko) | 경피 흡수형 제약 제제 | |
CN1895311A (zh) | 亲水性凝胶透皮贴片及其制备方法 | |
CN104983674A (zh) | 快速止痒、消除红肿、红疹及防蚊叮虫咬的外用药物 | |
TW202027743A (zh) | 含阿申那平貼附劑 | |
CN1864753A (zh) | 贴剂 | |
CN1251668C (zh) | 中药贴膏基质、使用该基质的中药贴膏及它们的制备方法 | |
CN1390582A (zh) | 生药材贴片 | |
CN1861059A (zh) | 含辣椒素的亲水性凝胶透皮贴片及其制备方法 | |
CN1414856A (zh) | 治疗瘙痒的外用制剂 | |
CN1695642A (zh) | 复方土荆皮凝胶及其制备方法 | |
US11229610B2 (en) | Cannabinoid and menthol gel compositions, patches and methods | |
CN108235684B (zh) | 一种软化疤痕的中药贴剂 | |
CN1254278C (zh) | 医用膏膜酊剂 | |
CN1548167A (zh) | 止血抗菌产品及其制造方法 | |
CN102631408A (zh) | 一种复方松节油纳米乳组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |